Eli Lilly and (LLY) Operating Margin: History & Chart

Eli Lilly and Company(LLY)

Drug Manufacturers - General · Indianapolis, IN

$1,123.86+0.00 (+0.00%)

Delayed quote: Sep 8, 2026, 3:59 PM EDT

About Eli Lilly and Company

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Indianapolis, IN

50,000 employees

www.lilly.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: David A. Ricks

View full financials

LLY Operating Margin Metrics

OPERATING MARGIN

43.92%

OPERATING MARGIN AVG TTM

44.54%

OPERATING MARGIN AVG 3Y

39.82%

OPERATING MARGIN AVG 5Y

35.61%

OPERATING MARGIN AVG 10Y

30.24%

OPERATING MARGIN AVG 15Y

26.81%

OPERATING MARGIN AVG 20Y

25.90%

CURRENT VS TTM AVG

-1.40%

CURRENT VS 3Y AVG

+10.30%

CURRENT VS 5Y AVG

+23.35%

CURRENT VS 10Y AVG

+45.26%

CURRENT VS 15Y AVG

+63.81%

CURRENT VS 20Y AVG

+69.56%

SECTOR MEDIAN · HEALTHCARE

14.90%

median of 90 covered companies

CURRENT VS SECTOR MEDIAN

+194.77%

vs the sector median at left

NAME	MARKET CAP	OPERATING MARGIN	TTM	3Y	5Y
Eli Lilly and Company (LLY)	$1.06T	43.92%	44.54%	39.82%	35.61%
Johnson & Johnson (JNJ)vs ›	$648.55B	26.81%	26.05%	26.47%	26.06%
AbbVie Inc. (ABBV)vs ›	$439.68B	29.32%	24.54%	25.94%	26.75%
Merck & Co., Inc. (MRK)vs ›	$366.74B	36.17%	33.84%	25.86%	23.98%
UnitedHealth Group Incorporated (UNH)vs ›	$364.02B	4.82%	6.16%	7.45%	7.80%
Roche Holding AG (RHHBY)vs ›	$344.74B	29.16%	25.33%	25.67%	27.00%
AstraZeneca PLC (AZN)vs ›	$248.20B	22.77%	20.95%	17.06%	15.08%
Thermo Fisher Scientific Inc. (TMO)vs ›	$224.09B	17.69%	18.04%	18.11%	20.54%
Amgen Inc. (AMGN)vs ›	$212.20B	33.18%	25.38%	28.78%	30.08%
Novo Nordisk A/S (NVO)vs ›	$200.54B	43.10%	42.74%	42.98%	42.70%

NAME

MARKET CAP

OPERATING MARGIN

TTM

Eli Lilly and Company (LLY)

$1.06T

43.92%

44.54%

39.82%

35.61%

Johnson & Johnson (JNJ)vs ›

$648.55B

26.81%

26.05%

26.47%

26.06%

AbbVie Inc. (ABBV)vs ›

$439.68B

29.32%

24.54%

25.94%

26.75%

Merck & Co., Inc. (MRK)vs ›

$366.74B

36.17%

33.84%

25.86%

23.98%

UnitedHealth Group Incorporated (UNH)vs ›

$364.02B

4.82%

6.16%

7.45%

7.80%

Roche Holding AG (RHHBY)vs ›

$344.74B

29.16%

25.33%

25.67%

27.00%

AstraZeneca PLC (AZN)vs ›

$248.20B

22.77%

20.95%

17.06%

15.08%

Thermo Fisher Scientific Inc. (TMO)vs ›

$224.09B

17.69%

18.04%

18.11%

20.54%

Amgen Inc. (AMGN)vs ›

$212.20B

33.18%

25.38%

28.78%

30.08%

Novo Nordisk A/S (NVO)vs ›

$200.54B

43.10%

42.74%

42.98%

42.70%

Operating Margin FAQ

What is the operating margin for Eli Lilly and Company (LLY)?

The operating margin for LLY stock is 43.92%.

Is Eli Lilly and Company's operating margin high or low?

The operating margin of 43.92% is 23% above its 5-year average of 35.61%, near the high end of its 5-year range (22.51%–47.65%).

What is the TTM average operating margin for Eli Lilly and Company (LLY)?

The TTM average operating margin for LLY stock is 44.54%.

What is the 3Y average operating margin for Eli Lilly and Company (LLY)?

The 3Y average operating margin for LLY stock is 39.82%.

What is the 5Y average operating margin for Eli Lilly and Company (LLY)?

The 5Y average operating margin for LLY stock is 35.61%.

What is the 10Y average operating margin for Eli Lilly and Company (LLY)?

The 10Y average operating margin for LLY stock is 30.24%.

What is the 15Y average operating margin for Eli Lilly and Company (LLY)?

The 15Y average operating margin for LLY stock is 26.81%.

What is the 20Y average operating margin for Eli Lilly and Company (LLY)?

The 20Y average operating margin for LLY stock is 25.90%.

DATE	OPERATING MARGIN
2026-06-30	39.08%
2026-03-31	44.70%
2025-12-31	45.49%
2025-09-30	47.65%
2025-06-30	45.80%
2025-03-31	42.49%
2024-12-31	42.84%
2024-09-30	39.77%
2024-06-30	39.09%
2024-03-31	31.20%
2023-12-31	34.14%
2023-09-30	37.28%
2023-06-30	28.13%
2023-03-31	24.64%
2022-12-31	30.23%
2022-09-30	29.36%
2022-06-30	26.89%
2022-03-31	34.10%
2021-12-31	30.89%
2021-09-30	31.47%
2021-06-30	22.51%
2021-03-31	25.75%
2020-12-31	32.06%
2020-09-30	26.02%
2020-06-30	26.81%
2020-03-31	29.82%
2019-12-31	26.23%
2019-09-30	28.50%
2019-06-30	27.91%
2019-03-31	24.78%
2018-12-31	24.81%
2018-09-30	27.86%
2018-06-30	29.52%
2018-03-31	28.39%
2017-12-31	12.47%
2017-09-30	21.51%
2017-06-30	22.57%
2017-03-31	21.38%
2016-12-31	18.29%
2016-09-30	19.05%
2016-06-30	18.16%
2016-03-31	17.41%
2015-12-31	13.84%
2015-09-30	20.24%
2015-06-30	19.19%
2015-03-31	19.14%
2014-12-31	17.23%
2014-09-30	14.22%
2014-06-30	17.96%
2014-03-31	18.50%
2013-12-31	17.10%
2013-09-30	26.76%
2013-06-30	26.42%
2013-03-31	25.77%
2012-12-31	21.29%
2012-09-30	20.93%
2012-06-30	21.47%
2012-03-31	25.08%
2011-12-31	20.44%
2011-09-30	26.21%
2011-06-30	27.53%
2011-03-31	29.96%
2010-12-31	24.70%
2010-09-30	30.99%
2010-06-30	31.00%
2010-03-31	31.16%
2009-12-31	22.46%
2009-09-30	30.32%
2009-06-30	30.17%
2009-03-31	34.76%
2008-12-31	28.96%
2008-09-30	27.87%
2008-06-30	25.20%
2008-03-31	26.39%
2007-12-31	23.27%
2007-09-30	26.38%
2007-06-30	27.06%
2007-03-31	26.80%
2006-12-31	24.91%
2006-09-30	27.17%
2006-06-30	25.70%
2006-03-31	27.58%
2005-12-31	25.30%
2005-09-30	25.92%
2005-06-30	24.21%
2005-03-31	24.18%
2004-12-31	26.75%
2004-09-30	26.33%
2004-06-30	25.46%
2004-03-31	27.09%
2003-12-31	25.68%
2003-09-30	29.58%
2003-06-30	27.83%
2003-03-31	28.52%
2002-12-31	30.20%
2002-09-30	32.11%

DATE

OPERATING MARGIN

2026-06-30

39.08%

2026-03-31

44.70%

2025-12-31

45.49%

2025-09-30

47.65%

2025-06-30

45.80%

2025-03-31

42.49%

2024-12-31

42.84%

2024-09-30

39.77%

2024-06-30

39.09%

2024-03-31

31.20%

2023-12-31

34.14%

2023-09-30

37.28%

2023-06-30

28.13%

2023-03-31

24.64%

2022-12-31

30.23%

2022-09-30

29.36%

2022-06-30

26.89%

2022-03-31

34.10%

2021-12-31

30.89%

2021-09-30

31.47%

2021-06-30

22.51%

2021-03-31

25.75%

2020-12-31

32.06%

2020-09-30

26.02%

2020-06-30

26.81%

2020-03-31

29.82%

2019-12-31

26.23%

2019-09-30

28.50%

2019-06-30

27.91%

2019-03-31

24.78%

2018-12-31

24.81%

2018-09-30

27.86%

2018-06-30

29.52%

2018-03-31

28.39%

2017-12-31

12.47%

2017-09-30

21.51%

2017-06-30

22.57%

2017-03-31

21.38%

2016-12-31

18.29%

2016-09-30

19.05%

2016-06-30

18.16%

2016-03-31

17.41%

2015-12-31

13.84%

2015-09-30

20.24%

2015-06-30

19.19%

2015-03-31

19.14%

2014-12-31

17.23%

2014-09-30

14.22%

2014-06-30

17.96%

2014-03-31

18.50%

2013-12-31

17.10%

2013-09-30

26.76%

2013-06-30

26.42%

2013-03-31

25.77%

2012-12-31

21.29%

2012-09-30

20.93%

2012-06-30

21.47%

2012-03-31

25.08%

2011-12-31

20.44%

2011-09-30

26.21%

2011-06-30

27.53%

2011-03-31

29.96%

2010-12-31

24.70%

2010-09-30

30.99%

2010-06-30

31.00%

2010-03-31

31.16%

2009-12-31

22.46%

2009-09-30

30.32%

2009-06-30

30.17%

2009-03-31

34.76%

2008-12-31

28.96%

2008-09-30

27.87%

2008-06-30

25.20%

2008-03-31

26.39%

2007-12-31

23.27%

2007-09-30

26.38%

2007-06-30

27.06%

2007-03-31

26.80%

2006-12-31

24.91%

2006-09-30

27.17%

2006-06-30

25.70%

2006-03-31

27.58%

2005-12-31

25.30%

2005-09-30

25.92%

2005-06-30

24.21%

2005-03-31

24.18%

2004-12-31

26.75%

2004-09-30

26.33%

2004-06-30

25.46%

2004-03-31

27.09%

2003-12-31

25.68%

2003-09-30

29.58%

2003-06-30

27.83%

2003-03-31

28.52%

2002-12-31

30.20%

2002-09-30

32.11%

Operating Margin: 43.92%

LLY Operating Margin

LLY Average Operating Margin Chart

LLY Current vs Average Operating Margin Chart

LLY Operating Margin Metrics

LLY Competitors' Operating Margin

Operating Efficiency

Operating Margin Formula & Definition

Operating Margin FAQ

LLY Operating Margin History

Related Metrics